Literature DB >> 11520801

In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells.

J A Sakai1, M Nagai, M B Brennan, C A Mora, S Jacobson.   

Abstract

Peripheral blood mononuclear cells (PBMCs) from patients with human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) proliferate spontaneously in vitro. This spontaneous lymphoproliferation (SP) is one of the immunologic hallmarks of HAM/TSP and is considered to be an important factor related to the pathogenesis of HAM/TSP. However, the cell populations involved in this phenomenon have not yet been definitively identified. To address this issue, the study directly evaluated proliferating cell subsets in SP with a flow cytometric method using bromodeoxyuridine and Ki-67. Although both CD4+ and CD8+ T cells proliferated spontaneously, the percentage of proliferating CD8+ T cells was 2 to 5 times higher than that of CD4+ T cells. In addition, more than 40% of HTLV-I Tax11-19-specific CD8+ T cells as detected by an HLA-A*0201/Tax11-19 tetramer proliferated in culture. In spite of this expansion of HTLV-I-specific CD8+ T cells, HTLV-I proviral load did not decrease. This finding will help elucidate the dynamics of in vivo virus-host immunologic interactions that permit the coexistence of high HTLV-I-specific CD8+ cytotoxic T-lymphocyte responses and high HTLV-I proviral load in HAM/TSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520801     DOI: 10.1182/blood.v98.5.1506

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  The NK cell as a new player in the pathogenesis of HTLV-I associated neurologic disease.

Authors:  Steven Jacobson
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

2.  Human T cell leukemia virus type 1 infection drives spontaneous proliferation of natural killer cells.

Authors:  Philip J Norris; Dale F Hirschkorn; Deborah A DeVita; Tzong-Hae Lee; Edward L Murphy
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

3.  Memory lineage relationships in HTLV-1-specific CD8+ cytotoxic T cells.

Authors:  Julie M Johnson-Nauroth; Jerome Graber; Karen Yao; Steve Jacobson; Peter A Calabresi
Journal:  J Neuroimmunol       Date:  2006-06-05       Impact factor: 3.478

4.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

5.  Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.

Authors:  Yoshihisa Yamano; Norihiro Takenouchi; Hong-Chuan Li; Utano Tomaru; Karen Yao; Christian W Grant; Dragan A Maric; Steven Jacobson
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Digital droplet PCR (ddPCR) for the precise quantification of human T-lymphotropic virus 1 proviral loads in peripheral blood and cerebrospinal fluid of HAM/TSP patients and identification of viral mutations.

Authors:  Giovanna S Brunetto; Raya Massoud; Emily C Leibovitch; Breanna Caruso; Kory Johnson; Joan Ohayon; Kaylan Fenton; Irene Cortese; Steven Jacobson
Journal:  J Neurovirol       Date:  2014-04-30       Impact factor: 2.643

Review 7.  Human T-cell lymphotropic virus type I and neurological diseases.

Authors:  Masahiro Nagai; Mitsuhiro Osame
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

8.  Lower numbers of circulating Natural Killer T (NK T) cells in individuals with human T lymphotropic virus type 1 (HTLV-1) associated neurological disease.

Authors:  L C Ndhlovu; J E Snyder-Cappione; K I Carvalho; F E Leal; C P Loo; F R Bruno; A R Jha; D Devita; A M Hasenkrug; H M R Barbosa; A C Segurado; D F Nixon; E L Murphy; E G Kallas
Journal:  Clin Exp Immunol       Date:  2009-09-02       Impact factor: 4.330

9.  Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Raya Massoud; Yoshimi Enose-Akahata; Yutaka Tagaya; Nazli Azimi; Asjad Basheer; Steven Jacobson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

10.  Phase 1 trial of IL-15 trans presentation blockade using humanized Mikβ1 mAb in patients with T-cell large granular lymphocytic leukemia.

Authors:  Thomas A Waldmann; Kevin C Conlon; Donn M Stewart; TatYana A Worthy; John E Janik; Thomas A Fleisher; Paul S Albert; William D Figg; Shawn D Spencer; Mark Raffeld; Jean R Decker; Carolyn K Goldman; Bonita R Bryant; Michael N Petrus; Stephen P Creekmore; John C Morris
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.